The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants

• Asıl Yazarlar: Wu Ye (Yazar), Xia Wu (Yazar), Xiaojia Wang (Yazar), Xiaoyu Wei (Yazar), Yuqian Tang (Yazar), Xianfeng Ouyang (Yazar), Yuping Gong (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Patients with chronic myeloid leukemia (CML) show resistance to tyrosine kinase inhibitors (TKIs) targeting ABL1 due to the emergence of BCR::ABL1 mutants, especially compound mutants during the treatment, which brings great challenges to clinical practice. Combination therapy is an effective strate...